Search research articles
Contact Us
Filters
Showing results (21-30 of 94) with videos related to
Page
of 10
Sort By:
Journal of Clinical Microbiology
|
April 19, 2013
Direct comparison of Xpert MTB/RIF assay with liquid and solid mycobacterial culture for quantification of early bactericidal activity
Xavier A Kayigire, Sven O Friedrich, Amour Venter, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
June 5, 2020
Transition from Restrictive to Obstructive Lung Function Impairment During Treatment and Follow-Up of Active Tuberculosis
Brian W Allwood, Elizna Maasdorp, Grace J Kim, et al.
Antimicrobial Agents and Chemotherapy
|
November 24, 2020
Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis
Elisa H Ignatius, Mahmoud Tareq Abdelwahab, Bronwyn Hendricks, et al.
BMC Medicine
|
February 25, 2016
Erratum to: Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials
Patrick P J Phillips, Carl M Mendel, Divan A Burger, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 7, 2011
Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?
Jakko van Ingen, Rob E Aarnoutse, Peter R Donald, et al.
Antimicrobial Agents and Chemotherapy
|
May 6, 2020
Reply to Kim et al., "Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment"
Andreas H Diacon, Veronique R De Jager, Rodney Dawson, et al.
American Journal of Respiratory and Critical Care Medicine
|
December 1, 2022
Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results
Kelly E Dooley, Bronwyn Hendricks, Nikhil Gupte, et al.
Antimicrobial Agents and Chemotherapy
|
January 29, 2020
Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis
Andreas H Diacon, Veronique R De Jager, Rodney Dawson, et al.
BMC Medicine
|
February 6, 2016
Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials
Patrick P J Phillips, Carl M Mendel, Divan A Burger, et al.
The Journal of Infectious Diseases
|
May 3, 2018
Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations
Robin J Svensson, Elin M Svensson, Rob E Aarnoutse, et al.
Page
of 10
Search research articles
Search
Showing results (21-30 of 94) with videos related to
Sort By:
Page
of 10
Journal of Clinical Microbiology
|
April 19, 2013
Direct comparison of Xpert MTB/RIF assay with liquid and solid mycobacterial culture for quantification of early bactericidal activity
Xavier A Kayigire, Sven O Friedrich, Amour Venter, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
June 5, 2020
Transition from Restrictive to Obstructive Lung Function Impairment During Treatment and Follow-Up of Active Tuberculosis
Brian W Allwood, Elizna Maasdorp, Grace J Kim, et al.
Antimicrobial Agents and Chemotherapy
|
November 24, 2020
Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis
Elisa H Ignatius, Mahmoud Tareq Abdelwahab, Bronwyn Hendricks, et al.
BMC Medicine
|
February 25, 2016
Erratum to: Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials
Patrick P J Phillips, Carl M Mendel, Divan A Burger, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 7, 2011
Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?
Jakko van Ingen, Rob E Aarnoutse, Peter R Donald, et al.
Antimicrobial Agents and Chemotherapy
|
May 6, 2020
Reply to Kim et al., "Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment"
Andreas H Diacon, Veronique R De Jager, Rodney Dawson, et al.
American Journal of Respiratory and Critical Care Medicine
|
December 1, 2022
Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results
Kelly E Dooley, Bronwyn Hendricks, Nikhil Gupte, et al.
Antimicrobial Agents and Chemotherapy
|
January 29, 2020
Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis
Andreas H Diacon, Veronique R De Jager, Rodney Dawson, et al.
BMC Medicine
|
February 6, 2016
Limited role of culture conversion for decision-making in individual patient care and for advancing novel regimens to confirmatory clinical trials
Patrick P J Phillips, Carl M Mendel, Divan A Burger, et al.
The Journal of Infectious Diseases
|
May 3, 2018
Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations
Robin J Svensson, Elin M Svensson, Rob E Aarnoutse, et al.
Page
of 10